Method for enhancing the therapeutic effect of fexapotide triflutate on lower urinary tract symptoms

JP2022532306A5Inactive Publication Date: 2024-11-01NYMOX CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2021563373
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-05-13
Filing Date
2020-05-07
Publication Date
2024-11-01
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

There is a need for treatments that can improve lower urinary tract symptoms without the risks and side effects of conventional drug therapy or surgical intervention, particularly for conditions like benign prostatic hyperplasia (BPH) that affect quality of life and can lead to serious complications.

Method used

The administration of fexapotide triflutate (FT) in multiple doses, spaced apart by at least one year, enhances therapeutic efficacy in treating lower urinary tract symptoms by improving both irritative and obstructive symptoms.

Benefits of technology

This regimen significantly reduces the progression of urinary flow deterioration, increases urinary peak flow rate, and decreases nocturia frequency, providing greater improvements compared to single-dose administration, with efficacy enhancements of up to 85% and 105% in urinary flow and 48% in nocturia reduction.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2020231727000001
    Figure 2020231727000001
  • Figure 2020231727000002
    Figure 2020231727000002
  • Figure 2020231727000003
    Figure 2020231727000003
Patent Text Reader

Abstract

A method for enhancing the therapeutic effect of fexapotide triflutate (TF) in the treatment of irritative and obstructive LUTS is disclosed, which comprises administering a composition containing FT at least twice within a period of one year or more. This method can enhance the therapeutic effect of nocturia and the improvement of urinary flow compared to the therapeutic effect achieved by administering the same total dose or a double dose of FT.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0003]

[0001] (Sequence Listing) This application includes a sequence listing submitted electronically in ASCII format, the contents of which are hereby incorporated by reference in their entirety.

[0002] (Cross - Reference to Related Applications) This application claims the priority of U.S. Provisional Patent Application No. 16 / 410,639, filed on May 13, 2019, the entire contents of which are hereby incorporated by reference.

[0003] Embodiments of the present invention include methods of enhancing the therapeutic effect of fexapotide triflutate (FT) by administering a composition containing FT at least twice during a period in which the therapeutic effect is higher than that obtained by administering FT once at a dose of 1 - fold, 2 - fold, or 4 - fold of a single dose. More specifically, embodiments include methods of enhancing the therapeutic effect of FT in the treatment of lower urinary tract symptoms by first administering FT and then administering at least one more dose of FT at least one year after the first administration.

Background Art

[0004] Many medical treatments and procedures essentially involve the removal or destruction of harmful or unwanted tissue. Examples of such treatments include surgical removal of cancerous or precancerous growths, destruction of metastatic tumors by chemotherapy, and reduction of glandular (e.g., prostatic) hyperplasia. Other examples include removal of unwanted facial hair, removal of warts, and removal of unwanted adipose tissue.

[0005] Benign prostatic hyperplasia (BPH) is common in older men and has symptoms that can affect the quality of life, such as interfering with activities and well - being. BPH can be a progressive disease associated with the risks of urinary retention, infections, bladder stones, and renal insufficiency. Many men with mild to moderate symptoms do well without treatment, but in others, troublesome symptoms and complications progress and may lead to medical therapy or surgery in some cases.

[0006] Benign prostatic hyperplasia (BPH) is histologically diagnosed as non-malignant proliferation of the smooth muscle and epithelial cells of the prostate. Lee C et al., "Endogenous and exogenous factors controlling benign prostatic growth," Prostate, 1997;31:131-138; Auffenberg GB et al., "Established medical treatments for benign prostatic hyperplasia," Urol Clin North Am, 2009;36:443-459. The exact etiology is unknown. As BPH progresses, benign prostatic hyperplasia (BPE), diagnosed by the size of the prostate (pathologically), may develop. Approximately 50% of men with histologically diagnosed BPH develop BPE. BPE can eventually lead to bladder outlet obstruction (BOO), also known as benign prostatic obstruction (BPO) when associated with BPE. BOO and BPO are diagnosed by urodynamics. Some patients present with BPE but do not have significant LUTS, and some patients present with LUTS and a significantly reduced quality of life but do not have BPE or BPH. See Park, HJ et al., "Urinary Tract Symptoms (LUTS) Associated with Benign Prostatic Hyperplasia (BPH)," World J. Mens Health, No. 31(3), 193-207 (2013).

[0007] Lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH) are generally classified into two types: 1) "Irritation" symptoms, also known as "storage" symptoms, and 2) "Obstruction" symptoms, also known as "voiding" symptoms. Symptoms of irritation and storage include urinary urgency, frequent urination, and nocturia (frequent urination after falling asleep at night). Symptoms of obstruction and voiding include weak urine flow, the need to strain or exert force to urinate, a feeling of incomplete bladder emptying, and frequent stopping and restarting of urination. Nocturia, in particular, is the most troublesome symptom, as it not only reduces sleep quality but also causes chronic fatigue and inconvenience to one's spouse.

[0008] In the United States and Europe, guidelines have been established to assist physicians in the treatment of LUTS, BPH, and LUTS / BPH. See Oelke M et al., European Association of Urology, Eur.Urol. July 2013;64(1):118-40. The guidelines describe various treatment options, from observation (WW) for men presenting with symptoms but not requiring medication or surgical intervention, to drug therapy and surgical intervention. The drug therapy guidelines recommend the use of alpha-blockers (alpha-adrenergic antagonists), 5α-reductase inhibitors (5ARIs), anti-muscarinic drugs (anticholinergics), PDE5 inhibitors (tadalafil), combination therapy, and vasopressin-like substances. Combination therapy with alpha-blockers and 5ARIs or anti-muscarinic drugs is also recommended.

[0009] Prostate surgery, such as transurethral resection of the prostate, is indicated for men with absolute indications or drug-resistant BPH, LUTS, or acute urinary retention (AUR). Indications for surgery include severe symptoms such as urinary retention, gross hematuria, urinary tract infections, and bladder stones. Minimally invasive treatments include transurethral microwave therapy and transurethral acupuncture. For men who cannot undergo surgery, prostate stents may be used as an alternative to catheter treatment. Despite the availability of various treatment options, the medical need for effective and safe medications to treat the troublesome symptoms that can result from benign prostatic hyperplasia remains unmet. These symptoms can lead to more serious problems such as chronic urinary tract infections, incontinence, acute and chronic urinary retention, and renal failure.

[0010] Drugs known to have the ability to destroy harmful or unwanted cells and tissues, thereby facilitating their removal or inhibiting their further growth, include U.S. Patent Application No. 14 / 808,713 filed July 24, 2015 ("Method for Reducing the Need for Surgery in Patients with Benign Prostatic Hyperplasia"), U.S. Patent Application No. 14 / 606,683 filed January 27, 2015 ("Method for Treating Diseases Requiring the Destruction or Removal of Cells"), U.S. Patent Application No. 14 / 738,551 filed June 12, 2015 ("Formulated Composition for Treating Diseases Requiring the Removal or Destruction of Unwanted Cellular Proliferations"), U.S. Patent Publication No. 2007 / 0237780 (abandoned), and U.S. Patent Publication This information is disclosed in U.S. Patent Application Publication No. 2003 / 0054990 (currently U.S. Patent No. 7,172,893), U.S. Patent Application Publication No. 2003 / 0096350 (currently U.S. Patent No. 6,924,266), U.S. Patent Application Publication No. 2003 / 0096756 (currently U.S. Patent No. 7,192,929), U.S. Patent Application Publication No. 2003 / 0109437 (currently U.S. Patent No. 7,241,738), U.S. Patent Application Publication No. 2003 / 0166569 (currently U.S. Patent No. 7,317,077), U.S. Patent Application Publication No. 2005 / 0032704 (currently U.S. Patent No. 7,408,021), and U.S. Patent Application Publication No. 2015 / 0148303 (currently U.S. Patent No. 9,243,035), the contents of which are incorporated herein by reference in their entirety.

[0011] One of the drugs disclosed in these studies is fexapotide triflutate (FT). FT has been shown to reduce prostate cells. In controlled clinical trials targeting BPH and some of its symptoms, the overall improvement seen with FT was greater than that with placebo, based on long-term observation.

[0012] There is a need for a treatment that can improve lower urinary tract symptoms without the risks and side effects of conventional drug therapy or without surgical intervention. There is a need for a treatment that can improve irritation, storage symptoms, obstruction, and voiding symptoms of the lower urinary tract without the risks and side effects of conventional drug therapy or without surgical intervention.

[0013] Throughout this description, including the preceding description of related technologies, all publicly available documents described herein (including all U.S. patents and published patent applications) are incorporated herein by reference in their entirety. The preceding description of related technologies does not constitute in any way prior art of any of the above documents, including any pending U.S. patent applications. Furthermore, the descriptions herein of any defects relating to the described products, methods, and / or apparatus do not limit any embodiments. In fact, aspects of the embodiments may include certain features of the described products, methods, and / or apparatus without being harmed by the defects described. [Overview of the Initiative]

[0014] In this field, there remains a need for novel, low-toxicity, and infrequent treatments (e.g., avoiding the need to take medication daily or weekly) that can improve the quality of life (QoL) of patients with lower urinary tract symptoms. There is also a need for treatments that improve irritation symptoms, storage symptoms, obstructive symptoms, and voiding symptoms in patients with lower urinary tract symptoms. Embodiments of the present invention satisfy these needs.

[0015] This disclosure is based on the discovery that certain peptides, including a specific peptide represented by the amino acid sequence Ile-Asp-Gln-Val-Leu-Ser-Arg-Ile-Lys-Leu-Glu-Ile-Lys-Arg-Cys-Leu (fexapotide triflutate or "FT"), can significantly improve lower urinary tract symptoms (LUTS) and, moreover, irritant storage symptoms and / or obstructive voiding symptoms in LUTS patients. This disclosure is also based on the discovery that specific methods of administering FT enhance the therapeutic effect of FT on LUTS-related diseases. Specifically, embodiments include a method of enhancing the therapeutic effect of FT by administering a composition containing at least FT twice for a period of time during which administering X amount of FT at least twice is more effective than administering 1, 2, or 4 times that amount of FT once. More specifically, embodiments include a method of enhancing the therapeutic effect of FT by administering FT first, and then administering FT at least once more, at least one year after the first administration.

[0016] The composition can be administered intramuscularly, orally, intravenously, intraperitoneally, intraventricularly (intravenous tissue), intraventricularly, intratumorally, intralesionally, intradermally, intrathecally, intranasally, intraocularly, intraarterially, locally, transrectally, transperitoneally, or transdermally, by aerosol, injection, bolus injection, implantation device, sustained-release system, etc. Alternatively, FT peptide can be expressed in vivo. This can be achieved by administering a gene that expresses FT peptide, administering a vaccine that induces such production, or introducing cells, bacteria, or viruses that express the peptide in vivo through genetic modification.

[0017] Another embodiment includes a method for improving nocturia by administering a composition containing X amount of FT at least twice over a period of at least one year. This method can provide a greater increase in mean frequency change than the increase in mean frequency change of nocturia from baseline achieved by administering a composition containing X amount and twice the amount of FT only once.

[0018] Another embodiment includes a method for improving the mean change in urinary peak flow rate (Qmax) from baseline by administering a composition containing X amount of FT at least twice over a period of at least one year. This method can provide a greater increase in mean change in urinary peak flow rate (Qmax) than the mean change in urinary peak flow rate (Qmax) from baseline achieved by administering a composition containing 2x and / or 4x amount of FT only once.

[0019] Another embodiment includes a method for suppressing urinary flow deterioration / obstruction, as measured by the inability to produce a urine volume of 125 ml or more (regardless of prior oral water intake), by administering a composition containing an amount X of FT at least twice within a period of at least one year. This method can suppress urinary flow deterioration / obstruction to a greater extent than the suppressive effect achieved by administering a composition containing twice the amount X and four times the amount X of FT only once.

[0020] Both the general description above and the detailed description below are illustrative and descriptive, and are intended to provide further explanation of the claimed embodiments. Other purposes, advantages, and features will be readily apparent to those skilled in the art from the detailed descriptions of each embodiment below. [Modes for carrying out the invention]

[0021] Before describing embodiments, it should be understood that the present invention is not limited to the specific methodologies, protocols, cell lines, vectors, and reagents described herein. Furthermore, it should be understood that the terminology used herein is solely for the purpose of describing specific embodiments and does not limit the scope of each embodiment of the present invention, which is limited only by the appended claims.

[0022] The terms and phrases used in this specification are defined as shown below, unless otherwise indicated. Throughout this specification, the singular forms "a", "an", and "the" include references to plural referents, unless the context clearly dictates otherwise. Thus, for example, reference to "a host cell" includes plural host cells, and reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art.

[0023] The amino acids and amino acid residues described herein may be referred to according to the commonly recognized one-letter or three-letter codes shown in the following table. [Table 1]

[0024] The hexapeptide triflutate ("FT") used in this specification represents a 17-mer peptide having the following amino acid sequence: Ile-Asp-Gln-Gln-Val-Leu-Ser-Arg-Ile-Lys-Leu-Glu-Ile-Lys-Arg-Cys-Leu (SEQ ID NO.1). FT is disclosed in U.S. Pat. Nos. 6,924,266, 7,241,738, 7,317,077, 7,408,021, 7,745,572, 8,067,378, 8,293,703, 8,569,446, and 8,716,247, and in U.S. Patent Application Publication Nos. 2017 / 0360885, 2017 / 0020957, 2016 / 0361380, and 2016 / 0215031. The disclosures of these patents and patent application publications are hereby incorporated by reference in their entirety. FT is represented as follows. SEQ ID NO.1 (Sequence No. 1): IDQQVLSRIKLEIKRCL or Ile-Asp-Gln-Gln-Val-Leu-Ser-Arg-Ile-Lys-Leu-Glu-Ile-Lys-Arg-Cys-Leu

[0025] The term "fragment" refers to a protein or polypeptide consisting of a contiguous subsequence of the amino acid sequence of a protein or peptide, including fragments that are naturally occurring, such as splice variants, and fragments that result from naturally occurring in vivo protease activity. Such fragments may be truncated at the amino terminus, carboxy terminus, and / or internally (e.g., by natural splicing). Such fragments may be prepared with or without an amino-terminal methionine. The term "fragment" includes identical or different fragments from the same protein or peptide having contiguous amino acid sequences, either common or not, which are linked directly or via a linker. One of ordinary skill in the art will be able to select fragments suitable for use in embodiments without undue experimentation using the guidelines and procedures outlined herein.

[0026] The term "variant" refers to a protein or polypeptide in which there are one or more amino acid substitutions, deletions, and / or insertions as compared to the amino acid sequence of the protein or peptide described herein, and includes naturally occurring allelic variants or alternative splicing variants of the protein or peptide thus described. The term "variant" includes substitutions of one or more amino acids in the peptide sequence by similar or homologous amino acid(s) or non-similar amino acid(s). There are many criteria for determining which amino acids may be recognized as similar or homologous (Gunnar von Heijne, Sequence Analysis in Molecular Biology, pages 123-39 (Academic Press, New York, NY, 1987)). Preferred variants include alanine substitutions at one or more amino acid positions. Other preferred substitutions include conservative substitutions that have little or no effect on the overall net charge, polarity, or hydrophobicity of the protein. Conservative substitutions are shown in Table 2 below. **Table 2** Table 3 shows another scheme for amino acid substitutions. [Table 3]

[0027] Other variants may consist of less conserved amino acid substitutions, such as selecting residues that have a more significantly different effect on (a) the structure of the polypeptide backbone in the substituted region, for example, as a sheet or helical conformation, (b) the molecular charge or hydrophobicity at the target site, or (c) the maintenance of side chain size. Generally, substitutions expected to have a more significant impact on function are: (a) substitution of glycine and / or proline with, deletion of, or insertion of another amino acid; (b) substitution of a hydrophilic residue, e.g., ceryl or threonyl, for (or by) a hydrophobic residue, e.g., leucyl, isoleucyl, phenylalanyl, valyl, or alanyl; (c) substitution of a cysteine ​​residue for (or by) any other residue; (d) substitution of an electrically positive side chain residue, e.g., lysyl, arginyl, or histidyl, for (or by) a negatively charged residue, e.g., glutamyl or aspartyl; or (e) substitution of a residue with a large side chain, e.g., phenylalanine, for (or by) one without such a side chain, e.g., glycine. Other variants include those designed to generate novel glycosylation sites and / or phosphorylation sites, or those designed to delete existing glycosylation sites and / or phosphorylation sites. The variants include at least one amino acid substitution at glycosylation sites, proteolytic cleavage sites, and / or cysteine ​​residues. The variants also include proteins and peptides that contain additional amino acid residues before or after the protein or peptide amino acid sequence on the linker peptide. For example, it is possible to add cysteine ​​residues to both the amino and carboxyl terms of the FT peptide to enable cyclization of the peptide by disulfide bond formation. The term “variant” also includes polypeptides having the FT amino acid sequence with at least one to 25 or more additional amino acids adjacent to either the 3' or 5' end of the peptide.

[0028] The term “derivative” refers to a chemically modified protein or polypeptide that is chemically modified not only by natural processes such as processing and other post-translational modifications, but also by chemical modification techniques, such as adding one or more polyethylene glycol molecules, sugars, phosphates, and / or other such molecules when they are not naturally attached to the wild-type protein or FT. Derivatives include salts. Such chemical modifications are well described in basic textbooks, in more detailed monographs, and in a large amount of research literature, and are well known to those skilled in the art. It will be recognized that the same type of modification may be present in several sites of a given protein or polypeptide to the same or different degrees. Also, a given protein or polypeptide may contain many types of modifications. Modifications can occur at any site of the protein or polypeptide, including the peptide backbone, amino acid side chains, and amino or carboxyl termini. Modifications include, for example, acetylation, acylation, ADP-ribosylation, amidation, covalent bonding of flavins, covalent bonding of heme moieties, covalent bonding of nucleotides or nucleotide derivatives, covalent bonding of lipids or lipid derivatives, covalent bonding of phosphatidylinositol, crosslinking, cyclization, disulfide bond formation, demethylation, covalent crosslinking, cysteine ​​formation, pyroglutamate formation, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodization, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, glycosylation, lipid attachment, sulfated amino acid addition to proteins mediated by transfer RNA, such as gamma-carboxylation, hydroxylation and ADP-ribosylation of glutamate residues, selenylation, sulfated amino acid addition, and arginylation, as well as ubiquitination.See, for example, Proteins--Structure And Molecular Properties, 2nd edition, T.E. Creighton, WH Freeman and Company, New York (1993) and Wold, F., "Posttranslational Protein Modifications: Perspectives and Prospects," in Posttranslational Covalent Modification Of Proteins, pp. 1-12, edited by BC Johnson, Academic Press, New York (1983); see Seifter et al., Meth. Enzymol. 182:626-646 (1990) and Rattan et al., "Protein Synthesis: Posttranslational Modifications and Aging," Ann. NYAcad. Sci. 663:48-62 (1992). The term "derivative" includes chemical modifications that result in a protein or polypeptide that is branched, branched and cyclic, or unbranched and cyclic. Circular, branched, and branched circular proteins or polypeptides can arise from post-translational natural processes and can also be created entirely synthetically.

[0029] The term "homologous" refers to a protein that is at least 60% identical to the amino acid sequence of FT, as determined by standard methods commonly used to compare the similarity of amino acid positions between two polypeptides. The degree of similarity or identity between two proteins is not limited, but can be found in: Computational Molecular Biology, edited by Lesk, AM, Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, edited by Smith, DW, Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, edited by Griffin, AM, and Griffin, HG, Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; Sequence Analysis Primer, edited by Gribskov, M. and Devereux, J., M Stockton Press, New York, 1991; and Carillo H. and Lipman, D., SIAM, J. Applied It is readily computable by known methods, including those described in Math., 48:1073 (1988). The preferred method for determining identity is designed to produce the greatest possible match between the sequences being tested. Methods for determining identity and similarity have been systematized into publicly available computer programs.

[0030] Useful and preferred computer programming methods for determining identity and similarity between two sequences include, but are not limited to, the GCG program package (Devereux, J. et al., Nucleic Acids Research, 12(1):387(1984)), BLASTP, BLASTN, and FASTA (Atschul, S. et al., J. Molec. Biol., 215:403-410(1990)). The BLAST X program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S. et al., NCBI NLM NIH Bethesda, Md.20894; Altschul, S. et al., J. Molec. Biol., 215:403-410(1990)). For example, computer algorithms such as GAP (University of Wisconsin Gene Computing Group, Madison, Wisconsin) are used to determine the percentage sequence identity of two proteins or polypeptides, placing them in parallel so that their respective amino acids are optimally matched (a "matched span" as determined by the algorithm).

[0031] A gap opening penalty (calculated as 3 times the mean diagonal; "mean diagonal" is the average of the diagonals of the comparison matrix used; "diagonal" is the score or number assigned to each complete amino acid match by a particular comparison matrix) and a gap elongation penalty (usually 1 / 10 of the gap opening penalty), as well as comparison matrices such as PAM250 or BLOSUM62, are used in combination with the algorithm. Standard comparison matrices (for the PAM250 comparison matrix, see Dayhoff et al.: Atlas of Protein Sequence and Structure, vol. 5, supp. 3; for the BLOSUM62 comparison matrix, see Henikoff et al., Proc. Natl. Acad. Sci USA, 89: 10915-10919) can also be used with the algorithm. The algorithm then calculates the percentage identity. Homogenies will, in some cases, typically have one or more amino acid substitutions, deletions, and / or insertions when compared to the corresponding protein or peptide.

[0032] The term "fusion protein" means a protein in which one or more peptides are recombinantly fused to or chemically conjugated (including covalent and non-covalent) a protein such as an antibody or an antibody fragment such as a Fab fragment or a short-chain Fv. The term "fusion protein" further means a multimer of peptides (i.e., dimers, trimers, tetramers and more multimers). Such multimers include homomeric multimers containing one peptide; heteromeric multimers containing two or more peptides; and heteromeric multimers containing at least one peptide and at least one other protein. Such multimers may be the result of hydrophobic, hydrophilic, ionic and / or covalent association, bonding or linking, may be formed by cross-linking using linker molecules, or indirectly, for example, by liposome formation.

[0033] The terms “peptide mimetic” or “mimetic” refer to biologically active compounds that mimic the biological activity of a peptide or protein but are no longer peptidic in their chemical properties, i.e., they no longer contain any peptide bonds (i.e., amide bonds between amino acids). In this specification, the term peptide mimetic is used in a broader sense and includes, in effect, molecules that are no longer completely peptidic, such as pseudopeptides, semipeptides, and peptoids. Examples of peptide mimetics in this broader sense (where a portion of a peptide is replaced with a structure lacking peptide bonds) are described below. Whether completely non-peptide or partially non-peptide, the peptide mimetic according to each embodiment provides a spatial arrangement of reactive chemical moieties that closely mimics the three-dimensional arrangement of the active groups of the peptide on which the peptide mimetic is based. As a result of this similarity in the geometric shape of the active site, the peptide mimetic has an effect on the biological system similar to the biological activity of a peptide.

[0034] The peptide mimes of embodiments of the present invention are preferably substantially similar to the peptides described herein in both three-dimensional shape and biological activity. Examples of methods for generating peptide mimes by structurally modifying peptides known in the art include inversion of the main chain chiral center, which leads to a D-amino acid residue structure, and the D-amino acid residue structure, particularly at the N-terminus, leads to enhanced stability against proteolytic degradation without undesirable activity. This example is described in the paper "Tritriated D-ala1-Peptide T Binding," Smith CS et al., Drug Development Res., 15, pp. 371-379 (1988). A second method is the modification of cyclic structures for stability, such as N-to-C interchain imides and lactams (Ede et al., Smith and Rivier (eds.), "Peptides: Chemistry and Biology," Escom, Leiden (1991), pp. 268-270). One example of this is given by conformationally restricted thymopentin-like compounds, such as those disclosed in U.S. Patent No. 4,457,489 (1985) by Goldstein, G. et al., the disclosure of which is incorporated herein by reference in its entirety. A third method involves substituting peptide bonds within a peptide with pseudopeptide bonds that provide resistance to proteolysis.

[0035] Several pseudopeptide bonds have been described that generally do not affect the peptide structure and biological activity. One example of this approach is substitution with retro-inverso pseudopeptide bonds ("Biologically active retroinverso analogues of thymopentin", Sisto A. et al., Rivier, JE and Marshall, GR (eds.), "Peptides, Chemistry, Structure and Biology", Escom, Leiden (1990), pp. 722-773, and Dalpozzo et al. (1993), Int. J. Peptide Protein Res., 41:561-566, incorporated herein). Following this modification, the amino acid sequence of the peptide may be identical to that of the peptide described above, except that one or more peptide bonds are replaced with retro-inverso pseudopeptide bonds. Preferably, the most N-terminal peptide bond is substituted, as such substitutions would confer resistance to proteolysis by exopeptidases acting on the N-terminus. Further modification is possible by substituting the amino acid chemical group with another chemical group of a similar structure. Another suitable pseudopeptide bond known to enhance stability to enzymatic cleavage with little to no loss of biological activity is the reduced isosterne pseudopeptide bond (Couder et al. (1993), Int. J. Peptide Protein Res., 41:181-184, incorporated herein by reference in whole).

[0036] Therefore, the amino acid sequences of these peptides may be identical to those of FT, except that one or more peptide bonds are replaced by isoster pseudopeptide bonds. Preferably, the most N-terminal peptide bond is substituted, as such substitution would provide resistance to proteolysis by exopeptidases acting on the N-terminus. The synthesis of peptides having one or more reducing isoster pseudopeptide bonds is known in the art (Couder et al. (1993), cited above). Other examples include the substitution of peptide bonds by introducing ketomethylene or methyl sulfide bonds.

[0037] The peptoid derivatives of the peptides described herein are equivalent to another type of peptide mimetic, in which the peptide bond is removed, thereby conferring resistance to proteolysis, while retaining structural determinants important for biological activity (Simon et al., 1992, Proc. Natl. Acad. Sci. USA, 89:9367-9371, which is incorporated herein in its entirety). Peptoids are oligomers of N-substituted glycine. Several N-alkyl groups have been described, each corresponding to the side chain of a native amino acid (Simon et al. (1992), cited above). It is possible to replace some or all of the amino acids of the peptide with the N-substituted glycine corresponding to the amino acids to be replaced.

[0038] The terms "peptide mimetic" or "mimicking" also include reverse D-peptides and enantiomers, as defined below.

[0039] The term "reverse D-peptide" refers to a biologically active protein or peptide consisting of D-amino acids arranged in the reverse order compared to the L-amino acid sequence of the peptide. For example, the carboxyl-terminal residue of an L-amino acid peptide becomes the amino-terminal residue of a D-amino acid peptide. For instance, the peptide ETESH becomes HdSdEdTdEd, where Ed, Hd, Sd, and Td are D-amino acids corresponding to L-amino acids, E, H, S, and T, respectively.

[0040] The term "enantiomer" refers to a biologically active protein or peptide in which one or more L-amino acid residues in the amino acid sequence of a peptide are replaced by corresponding D-amino acid residues.

[0041] As used herein, the term “composition” broadly refers to any composition containing FT and, optionally, additional activators. Such compositions may include dried formulations, aqueous solutions, or sterile compositions. Compositions containing FT can be used as hybridization probes. These probes can be stored in a lyophilized form and can be associated with stabilizers such as carbohydrates. For hybridization, the probes may be placed in an aqueous solution containing salts, e.g., NaCl; surfactants, e.g., sodium dodecyl sulfate (SDS); and other components, e.g., Denhart solution, skim milk, salmon sperm DNA, etc.

[0042] In embodiments in which additional activators are used with FT, the term “activator” is used to indicate any agent that provides a therapeutic effect to the patient in need, more preferably any agent that can remove unwanted cell and / or tissue growths. Suitable activators may include, but are not limited to, (i) anticancer activators (such as alkylating agents, topoisomerase I inhibitors, topoisomerase II inhibitors, RNA / DNA antimetabolites, and antimitotic agents), (ii) activators for treating benign growths, e.g., antiacne and antiverbal activators, (iii) antiandrogen compounds (cyproterone acetate (1α,2β-methylene-6-chloro-17α-acetoxy-6-dehydroprogesterone) tamoxifen, aromatase inhibitors), (iv) alpha-1 adrenergic receptor blockers (tamsulosin, terazosin, doxazosin, prazosin, bunazosin, indramin, alfuzosin, silodosin), (v) 5α-reductase inhibitors (finasteride, dutasteride), and (vi) phosphodiesterase type 5 (PDE5) inhibitors (tadalafil) and combinations thereof.

[0043] Throughout this specification, the terms “obstructive symptoms” and “voiding symptoms,” as well as the terms “irritant symptoms” and “storage symptoms,” are used interchangeably to refer to the symptoms of patients with lower urinary tract symptoms (LUTS). The European Urological Association (EAU) and American Urological Association (AUA) guidelines define LUTS as storage (irritant) symptoms affecting the lower urinary tract (LUT) (daytime frequent urination, urinary urgency, nocturia), voiding (obstructive) symptoms (pressure, weak urine flow, intermittent urine flow, feeling of incomplete bladder emptying), and post-voiding symptoms (post-void leakage). See Park, HJ et al., “Urinary Tract Symptoms (LUTS) Associated with Benign Prostatic Hyperplasia (BPH),” World J. Mens Health, No. 31(3), 193-207 (2013).

[0044] Improvement in obstructive and irritant symptoms can be measured according to techniques known in the art. For example, it is known that changes in urine weight can be determined by a uroflowmeter and a continuous plot of flow rate over time can be obtained. To enable accurate (±5%) measurement of Qmax, the plot is smoothed by an internal electronic filter. See Schafer W et al., "Examples of Urodynamic Testing: Uroflowmetry, Filled Cystometry and Pressure-Flow Studies," Neurol Urodynamics, Vol. 21, pp. 261-74 (2002). There are various methods for measuring nocturia, most of which involve the patient completing questionnaires before and after treatment to establish a baseline, and then determining the difference from the baseline after treatment (improvement, no improvement, worsening, etc.). Examples include scoring the nocturia question in the International Prostate Symptom Score (IPSS), evaluating the number of nighttime urinations (Boyarsky Symptom Score), the Madsen-Iversen Symptom Score, and the ICSmale Questionnaire. For example, see Chartier-Kastler et al., "Measurement of Nocturia in LUTS / BPH Patients and its Effects on Sleep Quality and QoL," Eur.Urol.Supp., Vol.5, pp.3-11 (2006). For measuring nocturia, it is preferable to calculate the mean change from baseline in the IPSS nocturia question (question 7). Question 7 asks patients how many times they had to get up to urinate between going to bed and waking up in the past month, with scores ranging from "none" (score 0) to "5 or more" (score 5).

[0045] Identifying patients with irritant and / or obstructive LUTS is typically performed by licensed, experienced healthcare professionals and is a separate diagnosis from benign prostatic hyperplasia (BPH). That is, with some overlap, patients with BPH do not necessarily have LUTS, and patients with LUTS do not necessarily have BPH. There are numerous techniques known in the industry that are available to identify patients with irritant or obstructive LUTS. For example, Chapple et al., "An International Consultation on Male LUTS," Fukuoka, Japan, September 30 - October 4, 2012, Societe Internatinoal d'Urologie, (2013) discloses established techniques for identifying patients suffering from obstructive symptoms ("Patient Assessment," Committee2, Section2.3, pp.61-80 (103-122)) and established techniques for identifying patients suffering from nocturia ("Assessment," Committee3, Section3.6, pp.155-162 (197-204)). Those skilled in the art will be able to identify patients with obstructive LUTS and patients with nocturia using the guidelines described above and in the published literature.

[0046] The inventors, while not intending to limit themselves to any particular theory or operation, have discovered that administering FT to mammals at least twice, with a period of more than one year between the first and second doses, unexpectedly improves the irritant and / or obstructive symptoms of LUTS patients. The inventors have found that this method of FT administration results in unexpectedly superior symptom improvement in patients with LUTS, including both irritant and obstructive urinary symptoms, compared to patients who received only one dose of FT. Patients with LUTS may also have BPH, and in one embodiment, patients with LUTS do not have BPH. It is clear that the population of patients with both LUTS and BPH is a subset of the overall population of patients with BPH. Therefore, methods for treating or improving BPH do not necessarily improve the irritant and / or obstructive symptoms of patients with LUTS.

[0047] In patients who received a single dose of 2.5 mg of FT, a slight improvement in the progression of urinary flow deterioration was observed after 3 months, but no significant improvement was observed compared to the control group. Subjects who received a single dose of twice the amount of 2.5 mg (2.5 mg x 2 doses) or four times the amount (2.5 mg x 4 doses) did not show a significantly better response compared to a single dose of 2.5 mg. The inventors unexpectedly found that even with the same total dose (e.g., 5 mg), subjects who received two doses (e.g., 2.5 mg each) with an interval of more than one year significantly suppressed the progression of urinary flow deterioration compared to subjects who received a single dose of twice the amount (5.0 mg) or four times the amount (10.0 mg).

[0048] Whether the effectiveness of the treatment has improved can be measured by determining the percentage difference between the improvement achieved according to the methods described herein and the improvement achieved with a single dose. Those skilled in the art will understand that different desired effectiveness levels will result in higher or lower numerical values ​​for the degree of improvement. For example, if administering X doses of FT twice over at least one year results in a patient failure rate of 5% (a lower number is better in this scenario), and administering 2X doses of FT at once (e.g., twice the dose of X doses of FT) results in a patient failure rate of 15%, then the effectiveness has improved by 66.7% ((15-5) / 15×100%).

[0049] In one embodiment, the inventors found that the method of administering FT as described herein reduced the percentage of LUTS patients with urinary flow deterioration / obstruction symptoms, compared to a control group, by the percentage of patients whose urine output was less than 125 ml regardless of prior water intake (Qmax), and reduced the percentage by at least 50%, about 50% to about 100%, about 60% to about 95%, about 65% to about 85%, about 70% to about 80%, or any value within these ranges. In this embodiment, the improvement in effectiveness compared to a single administration of the same total amount of FT was 75% or more, or about 81% to about 85%. The improvement in effectiveness compared to a single administration of twice the total amount of FT was 80% or more, or about 82% to about 85%.

[0050] In another embodiment, the inventors have found that the method of administering FT as described herein provides an improvement in efficacy, with improvements in urine flow rate, as measured by the mean change in peak flow rate (Qmax) from baseline, of about 75% or more, about 90% to about 200%, about 95% to about 150%, about 100% to about 120%, about 105% to about 115%, or any value within these ranges, compared to a control group. The inventors have also found that the method described herein provides an improvement in efficacy, with improvements of about 85% or more or about 95% to about 105% compared to a single administration of the same total amount of FT, and improvements of about 30% or more or about 40% to about 50% compared to a single administration of twice the total amount of FT.

[0051] In one embodiment, the inventors discovered that the method of administering FT as described herein resulted in an improvement in efficacy compared to a control group, with the change in mean nocturia frequency from baseline being approximately 25% or more, approximately 35% to approximately 75%, approximately 40% to approximately 60%, approximately 42% to approximately 55%, approximately 45% to approximately 50%, or any value within these ranges. Furthermore, the inventors discovered that the method described herein resulted in an improvement in efficacy of approximately 10% or more, or approximately 15% to approximately 25%, in mean nocturia frequency from baseline compared to a single administration of the same total amount of FT, and approximately 25% or more, or approximately 35% to approximately 40%, compared to a single administration of half the total amount of FT.

[0052] Embodiments include a method for enhancing the therapeutic effect of a composition containing FT when treating mammals having BPH and irritant or obstructive (or both) lump-shaped tumors (LUTS), comprising administering the composition containing FT first, and then administering FT at least once more, at least one year after the first administration. The composition may contain FT as the sole active agent, or FT may be administered in combination with another active agent. This method includes, but is not limited to, administering the composition containing FT intramuscularly, orally, intravenously, intraperitoneally, intracerebrally (in paramedical tissue), intravenously, intravesically, intrafocally, intraocularly, intraarterially, intrathecally, intratumorally, intranasally, topically, percutaneously, subcutaneously, intradermally, transrectally, or transperitoneally, either alone or in combination with a carrier. Embodiments may first identify a BPH patient suffering from irritant and / or obstructive lump-shaped tumors, and then administer the composition(s) containing FT according to the administration protocol described herein.

[0053] Any mammal may benefit from the use of the present invention. Mammals include humans, mice, rabbits, dogs, sheep, and other domesticated animals, as well as any mammal that has been treated or is treatable by a veterinarian, zookeeper, or wildlife conservation worker. Preferred mammals include humans, sheep, and dogs. In this specification, the terms “mammal” and “patient” are used interchangeably.

[0054] It will be apparent to those skilled in the art that other smaller fragments of FT can be selected such that these peptides have the same or similar biological activity. Those skilled in the art will also see that other fragments of FT can be selected such that these peptides have the same or similar biological activity. Therefore, the term "FT" as used in the embodiments encompasses these other fragments. Generally, the peptides of each embodiment have at least four amino acids, preferably at least five, and more preferably at least six amino acids.

[0055] Furthermore, embodiments of the present invention include therapeutic methods comprising administering a composition containing FTs formed by linking two or more FT sequences together with an additional activator. As long as the FTs have the desired biological activity, the two or more FT sequences will also have the desired biological activity.

[0056] FTs and their fragments, variants, derivatives, homologs, fusion proteins, and mimetic forms included in embodiments of the present invention can be produced using methods known to those skilled in the art. For example, recombinant DNA technology, protein synthesis, and methods such as the isolation of natural peptides, proteins, variants, derivatives, and homologs can be used. FTs and their fragments, variants, derivatives, homologs, fusion proteins, and mimetic forms can also be produced from other peptides, proteins, and their fragments, variants, derivatives, and homologs using methods known to those skilled in the art. Such methods include, but are not limited to, the use of proteases to cleave peptides or proteins into FTs. For example, the FT peptides described herein can be prepared using any of the methods disclosed in U.S. Patent Publications 6,924,266, 7,241,738, 7,317,077, 7,408,021, 7,745,572, 8,067,378, 8,293,703, 8,569,446 and 8,716,247, as well as in U.S. Patent Publications 2017 / 0360885, 2017 / 0020957, 2016 / 0361380 and 2016 / 0215031. The disclosures of these patent documents are incorporated herein by reference in their entirety.

[0057] If additional activators are used, one or more activators selected from the following may be used as such additional activators. (i) Anticancer agents (alkylating agents, topoisomerase I inhibitors, topoisomerase II inhibitors, RNA / DNA antimetabolites, and mitotic inhibitors, etc.), (ii) Activators for treating benign growths, e.g., antiacne and antiverbal agents (salicylic acid), (iii) Antiandrogen compounds (cyproterone acetate (1α,2β-methylene-6-chloro-17α-acetoxy-6-dehydroprogesterone) tamoxifen, aromatase inhibitors), (iv) α1-adrenergic receptor blockers (tamsulosin, terazosin, doxazosin, prazosin, bunazosin, indramin, alfuzosin, silodosin), (v) 5α-reductase inhibitors (finasteride, dutasteride), (vi) phosphodiesterase type 5 (PDE5) inhibitors (tadalafil) and combinations thereof. Preferably, the additional activator is selected from the group consisting of tamsulosin, finasteride, terazosin, doxazosin, prazosin, tadalafil, alfuzosin, silodosin, dutasteride, combinations of dutasteride and tamsulosin, and mixtures and combinations thereof.

[0058] The therapeutic compositions described herein may contain a certain amount of FT mixed with a pharmaceutically acceptable carrier. In some alternative embodiments, additional activators may be included in the same composition as FT and administered, and in other embodiments, the composition containing FT is administered by injection, while the additional activator is formulated in the form of an oral drug (gel, capsule, tablet, liquid, etc.). The carrier material may be water for injection, preferably water supplemented with other materials commonly found in solutions for administration to mammals. Typically, FT is administered in the form of a composition containing purified FT peptide (or chemically synthesized FT peptide) in combination with one or more physiologically acceptable carriers, excipients, or diluents. Neutral buffered saline or saline mixed with serum albumin are examples of suitable carriers. Preferably, the product is formulated as a lyophilized product with a suitable excipient (e.g., sucrose). Other standard carriers, diluents, and excipients may be included if desired. The compositions of each embodiment may also include buffers having a pH value within a suitable range known to those skilled in the art, such as Tris buffer with a pH of about 7.0 to 8.5, or acetate buffer with a pH of about 4.0 to 5.5. Sorbitol or a suitable substitute may be added to these.

[0059] Solid dosage forms for oral administration include, but are not limited to, capsules, tablets, pills, powders, and granules. In the case of such solid dosage forms, additional activators and / or FT may be mixed with at least one of the following: (a) one or more inert excipients (or carriers) such as sodium citrate or dicalcium phosphate; (b) fillers or bulking agents such as starch, lactose, sucrose, glucose, mannitol, and silicic acid; (c) binders such as carboxymethylcellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose, and acacia; (d) humectants such as glycerol; (e) disintegrants such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (f) solution coagulation retarders such as paraffin; (g) absorption enhancers such as quaternary ammonium compounds; (h) wetting agents such as acetyl alcohol and glycerol monostearate; (i) adsorbents such as kaolin and bentonite; and (j) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets, and pills, the dosage form may also include a buffer.

[0060] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. In addition to the active compound, the liquid dosage form may include inert diluents commonly used in the art, such as water or other solvents, solubilizers, and emulsifiers. Examples of emulsifiers include ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils such as cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil, and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols, fatty acid esters of sorbitan, or mixtures thereof.

[0061] In addition to such inert diluents, the composition may also contain adjuvants such as wetting agents, emulsifiers and suspending agents, sweeteners, flavorings and aromas.

[0062] The actual dose level of the active ingredient in the composition of the present invention may vary to obtain an effective amount of FT and additional activators for a particular composition to achieve the desired therapeutic response. Therefore, the selected dose level is determined by the desired therapeutic effect, route of administration, desired duration of treatment, and other factors.

[0063] In mammals, including humans, an effective dose can be administered based on body surface area. The interrelationships of doses (based on mg / M2 body surface area) for animals of various sizes and species, and for humans, were reported by EJ Freireich et al. in Cancer Chemother. Rep., 50(4):219 (1966). Body surface area can be roughly determined from the individual's height and weight (see, for example, Scientific Tables, Geigy Pharmaceuticals, Ardsley, New York, pp. 537-538 (1970)).

[0064] It will be understood that a specific dose level for any particular patient will vary depending on various factors such as body weight, overall health, sex, diet, time and route of administration, potency of the administered drug, absorption and elimination rates, combination with other drugs, and the severity of the particular disease being treated. It is desirable to administer the composition at least twice, with the second administration occurring at least one year after the first. In this embodiment, the interval between administrations of the composition may vary in the range of 1 to 15 years, 1 to 4 years, or 1 to 2 years.

[0065] A method for administering a composition containing FT according to embodiments of the present invention includes, but is not limited to, intramuscular, oral, intravenous, intraperitoneal, intraventricular (intravenous tissue), intraventricular, intratumoral, intralesional, intradermal, intrathecal, intranasal, intraocular, intraarterial, local, transrectal, transperitoneal, or transdermal administration of the composition by aerosol, injection, bolus injection, implantation device, sustained-release system, etc. For example, any administration method disclosed in U.S. Patents 6,924,266, 7,241,738, 7,317,077, 7,408,021, 7,745,572, 8,067,378, 8,293,703, 8,569,446 and 8,716,247, as well as in U.S. Patent Publications 2017 / 0360885, 2017 / 0020957, 2016 / 0361380 and 2016 / 0215031 may be used.

[0066] In one embodiment, at least one activator administered in combination with the FT peptide is selected from the group consisting of (1)-(40) below: (1) 5α-reductase inhibitor and / or anti-estrogen, (2) 5α-reductase inhibitor and / or aromatase inhibitor, (3) 5α-reductase inhibitor and / or 17β-HSD inhibitor, (4) 5α-reductase inhibitor, anti-estrogen, and aromatase inhibitor, (5) 5α-reductase inhibitor, anti-estrogen, and 17β-HSD inhibitor, (6) 5α-reductase (7) 5α-reductase inhibitors, aromatase inhibitors, antiestrogens, and 17β-HSD inhibitors, (8) 5α-reductase inhibitors, antiandrogens, and aromatase inhibitors, (9) 5α-reductase inhibitors, antiandrogens, and 17β-HSD inhibitors, (10) 5α-reductase inhibitors, antiandrogens, antiestrogens, and aromatase inhibitors, (11) 5α-reductase inhibitors, antiandrogens, aromatase inhibitors, and 17β-HSD inhibitors, (12) 5α- (13) 17β-HSD inhibitors, antiandrogens, aromatase inhibitors, antiestrogens, and 17β-HSD inhibitors, (14) 17β-HSD inhibitors, and aromatase inhibitors, (15) 17β-HSD inhibitors, aromatase inhibitors, and antiestrogens, (16) 17β-HSD inhibitors, antiandrogens, and antiestrogens, (17) 17β-HSD inhibitors, antiandrogens, and aromatase inhibitors, (18) 17β-HSD inhibitors, antiandrogens, antiestrogens, and aromatase inhibitors (19) anti-estrogens and aromatase inhibitors, (20) anti-estrogens, aromatase inhibitors and anti-androgens, (21) LHRH agonists or antagonists, 5α-reductase inhibitors and anti-estrogens, (22) LHRH agonists or antagonists, 5α-reductase inhibitors and aromatase inhibitors, (23) LHRH agonists or antagonists, 5α-reductase inhibitors and 17β-HSD inhibitors, (24) LHRH agonists or antagonists, 5α-reductase inhibitors,(25) Anti-estrogen and aromatase inhibitors, LHRH agonists or antagonists, 5α-reductase inhibitors, anti-estrogens and 17β-HSD inhibitors, (26) LHRH agonists or antagonists, 5α-reductase inhibitors, aromatase inhibitors, anti-estrogens and 17β-HSD inhibitors, (27) LHRH agonists or antagonists, 5α-reductase inhibitors, anti-androgens and anti-estrogens, (28) LHRH agonists or antagonists, 5α-reductase inhibitors (29) LHRH agonists or antagonists, 5α-reductase inhibitors, antiandrogens, and 17β-HSD inhibitors, (30) LHRH agonists or antagonists, 5α-reductase inhibitors, antiandrogens, anti-estrogens, and aromatase inhibitors, (31) LHRH agonists or antagonists, 5α-reductase inhibitors, antiandrogens, aromatase inhibitors, and 17β-HSD inhibitors, (32) LHRH agonists or antagonists (33) LHRH agonists or antagonists, 17β-HSD inhibitors, and antiestrogens, (34) LHRH agonists or antagonists, 17β-HSD inhibitors, and aromatase inhibitors, (35) LHRH agonists or antagonists, 17β-HSD inhibitors, aromatase inhibitors, and antiestrogens, (36) LHRH agonists or antagonists, 17β-HSD inhibitors, (37) LHRH agonists or antagonists, 17β-HSD inhibitors, antiandrogens, and aromatase inhibitors, (38) LHRH agonists or antagonists, 17β-HSD inhibitors, antiandrogens, antiestrogens, and aromatase inhibitors, (39) LHRH agonists or antagonists, antiestrogens, and aromatase inhibitors, and (40) LHRH agonists or antagonists, antiestrogens, aromatase inhibitors, and antiandrogens.

[0067] Based on tissue culture genetic array data, FT is a novel molecule that stimulates the caspase pathway (activation of caspases 7, 8, 10, caspase recruitment domains 6, 11, 14, and DIABLO), the tumor necrosis factor pathway (activation of TNF1, TNFSF6, TNFSF8, TNFSF9, CD70 ligand, TNFRSF19L, TNFRSF25, TRAF2, TRAF3, TRAF4, and TRAF6 receptor) and the BCL pathway (activation of BIK, HRK, BCL2L10, and BCL3) in vitro in prostatic epithelial cells. FT selectively induces loss of cell membrane integrity, mitochondrial metabolic arrest, RNA depletion, DNA lysis and aggregation, cell fragmentation, and cell disappearance. In the process of apoptosis, typical gradual changes in ultrastructure occur, including membrane disruption and swelling, gradually deepening nuclear infiltration, ultimately leading to membrane bleb formation, and finally cell death and fragmentation into apoptotic bodies. Histologically, typical apoptotic changes, in which apoptotic markers are immunohistochemically positive, are observed throughout the injection site for several weeks after treatment.

[0068] FT has been extensively studied in patients with BPH and low-grade (T1c) prostate cancer. The compound and a placebo control were administered rectally in over 1700 procedures across nine human clinical trials. In these large, long-term clinical trials in BPH patients, FT was administered at a concentration of 0.25 mg / ml (2.5 mg of FT would have covered approximately 15–20% of the prostate by volume). For example, see Shore et al., "The potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians," Ther Adv. Chronic Dis., 2(6), pp. 377-383 (2011). Therefore, it is preferable that a composition containing FT contains 2.5 mg of FT, and that such a composition be administered at least twice over a period of at least one year. The inventors unexpectedly discovered that such administration of FT resulted in greater improvement in obstructive and urinary symptoms of LUTS than single doses of 2.5 mg, single doses of 5.0 mg (simultaneous administration of 2.5 mg x 2 doses), 10.0 mg (simultaneous administration of 2.5 mg x 4 doses), and placebo control.

[0069] The following embodiments are provided to illustrate each embodiment of the present invention. However, it should be understood that each embodiment is not limited to the specific conditions or details described in these embodiments. Throughout this specification, any or all references to publicly available literature, including U.S. patents, are incorporated herein by reference. In particular, embodiments of the present invention expressly incorporate by reference examples contained in U.S. Patent Publications 6,924,266, 7,241,738, 7,317,077, 7,408,021, 7,745,572, 8,067,378, 8,293,703, 8,569,446 and 8,716,247, and U.S. Patent Publications 2017 / 0360885, 2017 / 0020957, 2016 / 0361380 and 2016 / 0215031. Each of these documents demonstrates that the specific peptides described therein are effective agents for in vivo inducing cell death in tissues such as muscle tissue, subcutaneous connective tissue, and dermis of normal rodents. [Examples]

[0070] The clinical trial involved a large number of patients with BPH, some of whom also had LUTS. All protocols were followed according to regulations and administered by physicians.

[0071] [Example 1] In a double-blind, ultrasound-guided study conducted by a urologist in a clinical setting, patients with BPH and possibly LUTS received either a) phosphate-buffered saline ("PBS") containing 2.5 mg of FT at pH 7.2, or b) PBS alone via intraprostatic injection. Patients were followed for 3 months to several years with regular physical examinations, clinical tests, and symptom assessments. Maximum urine flow rate (Qmax) was measured at 3 months and 12 months using a standard flowmeter for subjects who could urinate a sufficient volume (125 mL or more) to provide a valid test. Subjects who could not urinate 125 mL or more even after drinking the desired amount of water were classified as "Qmax-unable." The number of Qmax-unable subjects was compared across different groups. Surprisingly, subjects who received two doses of FT2.5mg showed a significantly better response compared to subjects who received a single treatment dose of 5mg (equivalent to two doses), subjects who received a single treatment dose of 10mg (equivalent to four doses), or the control group who received only one dose of FT2.5mg or only excipients. The results of Example 1 are shown in Table 4 below. [Table 4]

[0072] The results in Table 4 show that administering a composition containing FT at least twice over a period of at least one year significantly reduced the proportion of patients who could not achieve maximum urine output (Qmax) compared to the control group (approximately 77% improvement), compared to a single administration of double the amount of FT (approximately 81.4% improvement), and compared to a single administration of quadruple the amount of FT (approximately 83.3% improvement). Furthermore, the results in Table 4 show that administering double the amount of FT used in the multiple-dose method in a single dose, or quadruple the amount in a single dose, had little effect on reducing the proportion of patients who could not achieve Qmax compared to the control group. It is completely unexpected that administering FT twice over a period of more than one year reduced the proportion of patients who could not achieve Qmax by 81.4% compared to the control group, even though single administrations of double and quadruple the amount of the same activator had little effect.

[0073] [Example 2] In a double-blind, ultrasound-guided study conducted by a urologist in a clinical setting, patients with BPH and, in some cases, LUTS received intraprostatic injections of one of the following methods: a) pH 7.2 phosphate-buffered saline ("PBS") containing 2.5 mg of FT, b) PBS containing 5.0 mg of FT, c) two doses of PBS containing 2.5 mg of FT with an interval of less than one year, or d) 10 L of PBS alone. Patients were followed for 3 months to several years with regular physical examinations, clinical tests, and symptom assessments. Maximum urine flow rate (Qmax) was measured at 3 months and 12 months or later by flowmeter measurement using a standard method in subjects who could excrete a sufficient volume of urine (125 mL or more) to provide a valid test. Maximum flow rate measurements were evaluated by a blinded central radiologist. Changes in mean maximum flow rate from baseline were compared across multiple different groups. Surprisingly, subjects who received two doses of FT2.5mg showed a significantly better response compared to subjects who received a single treatment dose of 5mg (equivalent to two doses), subjects who received a single treatment dose of 10mg (equivalent to four doses), or the control group who received only the excipient once. The results of Example 2 are shown in Table 5 below. [Table 5]

[0074] The results in Table 5 show that administering the FT-containing composition at least twice over a period of at least one year significantly improved the maximum flow rate, as measured by the mean change from baseline, compared to the control group (approximately 111% improvement), compared to a single administration of twice the amount of FT (approximately 102% improvement), and compared to a single administration of four times the amount of FT (approximately 47% improvement).

[0075] [Example 3] In a double-blind, ultrasound-guided clinical setting, patients with BPH and possibly LUTS received intraprostatic injections of one of the following methods: a) phosphate-buffered saline ("PBS") containing 2.5 mg of FT at pH 7.2, b) PBS containing 5.0 mg of FT, c) two doses of PBS containing 2.5 mg of FT spaced less than one year apart, or d) 10 L of PBS alone. Patients were followed up for 3 months to several years with regular physical examinations, clinical tests, and symptom assessments. The mean difference between baseline nocturia scores and follow-up scores was calculated for subjects treated with FT (one dose of 2.5 mg of FT, one dose of 0.5 mg of FT, and two doses of 2.5 mg spaced more than one year apart) and for a control group treated with placebo (nocturia scores were the values ​​provided in IPSS Question #7). Surprisingly, subjects who received two doses of 2.5 mg with an interval of more than one year showed a statistically significant improvement in the average number of nocturia episodes. On the other hand, when a larger dose was administered once, no statistically significant improvement was observed, even though the total dose was the same. The results of Example 3 are shown in Table 6 below. [Table 6]

[0076] The results in Table 6 show that administering the FT-containing composition at least twice over a period of at least one year resulted in an approximately 48% improvement in the mean change from baseline in the nocturia score compared to the control group, an approximately 37% improvement compared to a single dose of the same amount, and an approximately 19.4% improvement compared to a single dose of twice the amount.

[0077] The results of the above examples provide remarkable data, regardless of whether the patient has BPH but also LUTS. Therefore, patients with BPH but no LUTS will not necessarily experience the improvement results provided in the examples. Consequently, in such patients, the results are expected to be unfavorably distorted, as they will not necessarily show improvement in irritant and / or obstructive LUTS, starting from a baseline with little to no irritant and / or obstructive LUTS. Therefore, it is thought that identifying BPH patients who also have LUTS and administering the FT-containing composition to such patients using the method described herein will yield even greater improvements in the following symptoms: (a) a reduction in the percentage of patients who cannot achieve Qmax, (b) improvement in mean flow rate (Qmax) from baseline, and (c) improvement in mean change in nocturia score from baseline. Each of these is expected to result in greater improvements than those shown in Examples 1-3 above.

Claims

1. A pharmaceutical agent for use in enhancing the therapeutic effect of a pharmaceutical agent in the treatment of lower urinary tract symptoms (LUTS), the pharmaceutical agent comprising at least a first composition and a second composition comprising fexapotide triflutate (FT), the first composition comprising a first amount of FT and neutral buffered saline, and being initially administered to a patient identified as suffering from LUTS, and the second composition comprising a second amount of FT and neutral buffered saline, and being again administered to the patient identified as suffering from LUTS at least one year after the initial administration, wherein when the first composition and the second composition are administered in a total amount, the sum of the first amount and the second amount, the degree of improvement in at least one symptom of LUTS is greater than the degree of improvement in at least one symptom of LUTS when the total amount of FT or twice the total amount of FT is administered once.

2. 2. The pharmaceutical agent of claim 1, wherein the first composition and the second composition contain fexapotide triflutate at a concentration of 2.5 mg / L.

3. 2. The pharmaceutical agent of claim 1, wherein the first composition and the second composition are administered by a method selected from the group consisting of oral administration, subcutaneous administration, intradermal administration, intranasal administration, intravenous administration, intramuscular administration, intrathecal administration, intranasal administration, intratumoral administration, topical administration, rectal administration, transperitoneal administration, and transdermal administration.

4. The pharmaceutical agent described in claim 1, wherein the patient identified as suffering from LUTS has LUTS hypersensitivity symptoms, the symptoms being selected from the group consisting of daytime frequent urination, urgency and nocturia.

5. The pharmaceutical agent according to claim 4, wherein the hypersensitivity symptom is nocturia.

6. The pharmaceutical agent described in claim 1, wherein the patient identified as suffering from LUTS has obstructive symptoms of LUTS, the symptoms being selected from the group consisting of a feeling of pressure, weak urinary stream, intermittent urinary flow and a feeling of residual urine.

7. The pharmaceutical agent of claim 6, wherein when the first and second compositions are administered to a patient identified as suffering from an obstructive symptom of LUTS, the proportion of patients who are unable to void sufficient urine volume (greater than 125 mL) is reduced by 81% to 85% compared to when the same total amount of FT is administered only once.

8. The pharmaceutical agent of claim 6, wherein administration of the first and second compositions to the patient identified as suffering from an obstructive symptom of LUTS results in a 95% to 105% improvement in mean change in peak flow (Qmax) from baseline compared to administration of the same total amount of FT only once.